Vertex Pharmaceuticals Incorpor

Historical 13F Holders

Symbol
VRTX
CUSIP
92532F100
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 92532F100 since 12/18/2024, newest first.

Filer % of Class Filed
Capital World Investors 13G/A Amendment 4 10.1% 5/14/2026
Event 3/31/2026
Capital Research Global Investors 13G/A Amendment 2 8.3% 5/14/2026
Event 3/31/2026
Vanguard Capital Management LLC 13G 7.5% 4/30/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 11 0% 3/27/2026
Event 3/13/2026
Capital Research Global Investors 13G/A Amendment 1 6.8% 2/12/2026
Event 12/31/2025
Capital Research Global Investors 13G 5.7% 5/13/2025
Event 3/31/2025
Capital World Investors 13G/A Amendment 3 11.2% 2/13/2025
Event 12/31/2024
FMR LLC 13G/A Amendment 2
3.6% 2/12/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 66 346 k $180 M
2026 Q2 1,839 433 M $121 B
2026 Q1 1,777 238 M $106 B
2025 Q4 1,754 242 M $110 B
2025 Q3 1,607 239 M $93.4 B
2025 Q2 1,652 243 M $108 B
2025 Q1 1,703 241 M $117 B
2024 Q4 1,660 237 M $95.4 B
2024 Q3 1,644 243 M $113 B
2024 Q2 1,646 245 M $115 B
2024 Q1 1,594 248 M $103 B
2023 Q4 1,535 246 M $99.9 B
2023 Q3 1,365 237 M $82.3 B
2023 Q2 1,355 238 M $83.4 B
2023 Q1 1,273 241 M $75.1 B
2022 Q4 1,296 251 M $72.3 B
2022 Q3 1,204 240 M $69.3 B
2022 Q2 1,171 236 M $66.1 B
2022 Q1 1,138 237 M $61.3 B
2021 Q4 1,108 231 M $50.6 B
2021 Q3 997 232 M $41.9 B
2021 Q2 1,047 234 M $46.9 B
2021 Q1 1,067 237 M $50.7 B
2020 Q4 1,037 241 M $57.4 B
2020 Q3 1,010 243 M $66.1 B
2020 Q2 1,024 244 M $70.9 B
2020 Q1 919 248 M $59.1 B
2019 Q4 877 248 M $54.3 B
2019 Q3 770 248 M $42.1 B
2019 Q2 785 248 M $45.5 B
2019 Q1 795 247 M $45.4 B
2018 Q4 760 247 M $40.9 B
2018 Q3 759 249 M $47.9 B
2018 Q2 745 244 M $41.5 B
2018 Q1 735 243 M $39.5 B
2017 Q4 691 240 M $36.0 B
2017 Q3 661 238 M $36.1 B
2017 Q2 616 236 M $30.4 B
2017 Q1 571 237 M $25.9 B
2016 Q4 527 237 M $17.4 B
2016 Q3 525 241 M $21.0 B
2016 Q2 524 240 M $20.7 B
2016 Q1 529 242 M $18.8 B
2015 Q4 558 237 M $29.9 B
2015 Q3 549 237 M $24.6 B
2015 Q2 532 230 M $28.4 B
2015 Q1 507 234 M $27.6 B
2014 Q4 518 232 M $27.6 B
2014 Q3 479 234 M $26.2 B
2014 Q2 467 232 M $22.0 B
2014 Q1 435 224 M $15.8 B